Brian Gastman
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Brian Gastman

Plastic Surgery
9500 Euclid Avenue, A60, Cleveland Clinic, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
9500 Euclid Avenue, A60, Cleveland Clinic, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Gastman is a Plastic Surgeon in Cleveland, Ohio. Dr. Gastman is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Angiosarcoma of the Scalp, Tissue Biopsy, and Osteotomy.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Residency
University of Pittsburgh Medical Center & Children's Hospital of Pittsburgh
Specialties
Plastic Surgery
Licenses
Otolaryngology in MD
Board Certifications
American Board Of Plastic Surgery, 2006
Fellowships
Washington University St. Louis Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
View 13 Less Insurance Carriers -

Locations

9500 Euclid Avenue, A60, Cleveland Clinic, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1B, Single Arm Study of Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of the Head and Neck to Assess for Pathologic Responses in the Tumor Microenvironment
A Phase 1B, Single Arm Study of Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of the Head and Neck to Assess for Pathologic Responses in the Tumor Microenvironment
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug, Other
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Pembrolizumab
Study Phase: Phase 2
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Adjuvant Melanoma Setting
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Adjuvant Melanoma Setting
Enrollment Status: Completed
Publish Date: July 29, 2024
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drugs: 6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Study Phase: Phase 1/Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 8 Less Clinical Trials

152 Total Publications

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Similar Doctors
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Rod P. Rezaee
Otolaryngology | Plastic Surgery
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Rod P. Rezaee
Otolaryngology | Plastic Surgery

University Hospitals Medical Group Inc

3999 Richmond Rd, 
Beachwood, OH 
 (7.4 miles away)
216-593-5500
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rod Rezaee is an Otolaryngologist and a Plastic Surgeon in Beachwood, Ohio. Dr. Rezaee is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Salivary Gland Tumors, Throat Cancer, Laryngeal Cancer, Gastrostomy, and Laryngectomy. Dr. Rezaee is currently accepting new patients.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Anthony P. Tufaro
Plastic Surgery
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Anthony P. Tufaro
Plastic Surgery

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
216-444-5433
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Tufaro is a Plastic Surgeon in Cleveland, Ohio. Dr. Tufaro is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Skin Carcinoma, Osteotomy, and Tissue Biopsy. Dr. Tufaro is currently accepting new patients.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Brock Generalovich
Plastic Surgery
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Brock Generalovich
Plastic Surgery

Triad Health Services LLC

7645 Market St, Suite 210, 
Youngstown, OH 
 (60.2 miles away)
330-726-3724
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brock Generalovich is a Plastic Surgeon in Youngstown, Ohio. Dr. Generalovich is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Rhinophyma, Melanoma, Congenital Generalized Lipodystrophy, and Familial Partial Lipodystrophy. Dr. Generalovich is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gastman's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile